Nkarta, Inc. - NKTX STOCK NEWS

Nkarta, Inc. reported positive preliminary data from its NKX101 and NKX019 Phase 1 studies in patients with relapsed/refractory AML and NHL, validating its CAR NK cell therapy platform. Financial results for Q2 2022 showed a net loss of $27.0 million or $0.61 per share. Nkarta held $415.0 million in cash and equivalents as of June 30, 2022, with R&D expenses at $21.0 million. The company anticipates further clinical data by year-end 2022, including safety and activity results at increased dosages. Nkarta aims to leverage this data for advancing its promising cancer therapies.

Nkarta, Inc. (Nasdaq: NKTX) recently announced the promotions of Ralph Brandenberger, PhD, to Chief Technical Officer and Yvonne Li, MBA, to Chief Administrative Officer. These changes are part of Nkarta's leadership evolution as it prepares for the commercialization of its off-the-shelf NK cell therapies. Dr. Brandenberger brings over 20 years of experience in biopharmaceutical manufacturing, while Ms. Li has nearly 25 years in corporate finance. Their leadership is expected to be vital as Nkarta advances in developing engineered NK cell therapies for cancer treatment.

Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company focused on engineered NK cell therapies for cancer, will present at the Cowen 3rd Annual Oncology Innovation Summit on June 2, 2022, at 11:00 a.m. ET. The event will feature a fireside chat, and a simultaneous webcast will be accessible on Nkarta's website. A replay will be available for four weeks following the event. Nkarta is advancing off-the-shelf NK cell therapies utilizing advanced technologies to enhance anti-tumor activity and improve patient access.

Nkarta, Inc. (Nasdaq: NKTX) has appointed Dr. David R. Shook as Vice President of Clinical Development, set to lead clinical and regulatory activities. Dr. Shook, a pioneer in NK cell therapy, previously directed Nkarta’s NKX101 and NKX019 programs. Kanya Rajangam, MD, PhD, resigns as Chief Medical Officer, effective June 5, 2022. Nkarta continues progressing in its clinical trials, with NKX101 and NKX019 showing early anti-tumor activity. Updated data is expected to be presented at a medical meeting later this year.

Nkarta, Inc. (Nasdaq: NKTX) reported positive preliminary results from its NKX101 and NKX019 Phase 1 trials for treating relapsed/refractory AML and NHL. In NKX101, 60% of AML patients achieved complete responses, with MRD negativity observed in two cases. NKX019 showed a 50% complete response rate in NHL patients. Both therapies demonstrated a favorable safety profile, unlike traditional CAR T cell treatments. Following a $230 million public offering, Nkarta holds over $400 million in liquid assets, ensuring operational funding into 2025.

Nkarta, Inc. (Nasdaq: NKTX) has successfully completed a public offering of 15,333,334 shares of its common stock, raising approximately $230 million. Each share was priced at $15.00, including an additional 2,000,000 shares purchased through the underwriters’ full exercise of their option. The funds will support the continued clinical development of NKX101 and NKX019, preclinical studies, and the expansion of manufacturing capabilities. The offering was conducted under a SEC shelf registration statement effective since September 2, 2021.

Nkarta, Inc. (Nasdaq: NKTX) announced an underwritten public offering of 13,333,334 shares at $15.00 per share, aiming to raise approximately $200 million in gross proceeds. The offering includes a 30-day option for underwriters to purchase up to 2,000,000 additional shares. Proceeds will support the clinical development of NKX101 and NKX019, preclinical studies, and enhance manufacturing capabilities. The offering is set to close around April 28, 2022, pending standard conditions. Cowen, SVB Securities, Evercore ISI, and Stifel serve as joint book-running managers.

Nkarta, Inc. (Nasdaq: NKTX) announced a proposed underwritten public offering to issue and sell $150 million of common stock, with an option for underwriters to purchase an additional $22.5 million. The offering is subject to market conditions, with no guarantee of completion. Proceeds will fund clinical development of NKX101 and NKX019, preclinical studies, internal manufacturing capabilities, and general corporate purposes. The offering follows SEC guidelines and will be conducted through a shelf registration statement.

Nkarta, Inc. (Nasdaq: NKTX) reported positive Phase 1 results for its CAR NK cell therapies, NKX101 and NKX019, focusing on hematologic malignancies. In NKX101, 60% of patients with relapsed/refractory AML achieved complete responses, with 2 being MRD negative. NKX019 demonstrated an 83% overall response rate in relapsed/refractory NHL, with a 50% complete response rate. Both therapies exhibited a favorable safety profile, with no severe toxicities reported. Nkarta continues to evaluate higher doses in ongoing clinical trials, with further data expected at future medical meetings.